{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T12:48:32Z","timestamp":1774615712700,"version":"3.50.1"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Beijing Talents Fund","award":["2014000021223ZK26"],"award-info":[{"award-number":["2014000021223ZK26"]}]},{"DOI":"10.13039\/501100009331","name":"Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support","doi-asserted-by":"crossref","award":["ZYLX201603"],"award-info":[{"award-number":["ZYLX201603"]}],"id":[{"id":"10.13039\/501100009331","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100009592","name":"Beijing Municipal Science and Technology Commission","doi-asserted-by":"crossref","award":["Z151100003915074"],"award-info":[{"award-number":["Z151100003915074"]}],"id":[{"id":"10.13039\/501100009592","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Bayer Pharmaceuticals"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.ejca.2018.04.007","type":"journal-article","created":{"date-parts":[[2018,6,19]],"date-time":"2018-06-19T09:19:08Z","timestamp":1529399948000},"page":"1-7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"special_numbering":"C","title":["Sorafenib in combination with gemcitabine plus cisplatin chemotherapy in metastatic renal collecting duct carcinoma: A prospective, multicentre, single-arm, phase 2 study"],"prefix":"10.1016","volume":"100","author":[{"given":"Xinan","family":"Sheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dengfeng","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianlin","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fangjian","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaodong","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuanliang","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhihong","family":"Chi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Si","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siming","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lili","family":"Mao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Lian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bixia","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xieqiao","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Kong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl 2","key":"10.1016\/j.ejca.2018.04.007_bib1","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1038\/modpathol.2009.70","article-title":"Uncommon and recently described renal carcinomas","volume":"22","author":"Srigley","year":"2009","journal-title":"Mod Pathol"},{"issue":"1","key":"10.1016\/j.ejca.2018.04.007_bib2","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0022-5347(06)00502-7","article-title":"Collecting duct (Bellini duct) renal cell carcinoma: a nationwide survey in Japan","volume":"176","author":"Tokuda","year":"2006","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.ejca.2018.04.007_bib3","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.eururo.2007.01.070","article-title":"Collecting duct renal cell carcinoma: a matched analysis of 41 cases","volume":"52","author":"Karakiewicz","year":"2007","journal-title":"Eur Urol"},{"issue":"9","key":"10.1016\/j.ejca.2018.04.007_bib4","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1097\/PAS.0b013e3182635954","article-title":"Carcinoma of the collecting ducts of Bellini and renal medullary carcinoma: clinicopathologic analysis of 52 cases of rare aggressive subtypes of renal cell carcinoma with a focus on their interrelationship","volume":"36","author":"Gupta","year":"2012","journal-title":"Am J Surg Pathol"},{"issue":"5","key":"10.1016\/j.ejca.2018.04.007_bib5","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1016\/j.juro.2007.01.063","article-title":"Prospective Multicenter Phase II Study of Gemcitabine Plus Platinum Salt for Metastatic Collecting Duct Carcinoma: results of a GETUG (Groupe d'Etudes des Tumeurs Uro-G\u00e9nitales) Study","volume":"177","author":"Oudard","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.ejca.2018.04.007_bib6","doi-asserted-by":"crossref","first-page":"17009","DOI":"10.1038\/nrdp.2017.9","article-title":"Renal cell carcinoma","volume":"3","author":"Hsieh","year":"2017","journal-title":"Nat Rev Dis Prim"},{"issue":"3","key":"10.1016\/j.ejca.2018.04.007_bib7","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.eururo.2016.11.020","article-title":"A systematic review and meta-analysis comparing the effectiveness and adverse effects of different systemic treatments for non-clear cell renal cell carcinoma","volume":"71","author":"Fern\u00e1ndez-Pello","year":"2017","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.ejca.2018.04.007_bib8","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3816\/CGC.2009.n.010","article-title":"Carcinoma of the collecting ducts of Bellini of the kidney: adjuvant chemotherapy followed by multikinase inhibition with sunitinib","volume":"7","author":"Staehler","year":"2009","journal-title":"Clin Genitourin Canc"},{"issue":"1\u20132","key":"10.1016\/j.ejca.2018.04.007_bib9","first-page":"44","article-title":"Sorafenib induces therapeutic response in a patient with metastatic collecting duct carcinoma of kidney","volume":"32","author":"Ansari","year":"2009","journal-title":"Onkologie"},{"issue":"2","key":"10.1016\/j.ejca.2018.04.007_bib10","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s10147-010-0116-z","article-title":"Metastatic collecting duct carcinoma of the kidney responded to sunitinib","volume":"16","author":"Miyake","year":"2011","journal-title":"Int J Clin Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2018.04.007_bib11","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1158\/1535-7163.MCT-08-0013","article-title":"Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling","volume":"7","author":"Wilhelm","year":"2008","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"10.1016\/j.ejca.2018.04.007_bib12","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.ejca.2018.04.007_bib13","doi-asserted-by":"crossref","first-page":"4836","DOI":"10.1158\/1078-0432.CCR-07-4123","article-title":"A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel","volume":"14","author":"Flaherty","year":"2008","journal-title":"Clin Canc Res"},{"issue":"4_suppl","key":"10.1016\/j.ejca.2018.04.007_bib14","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.4_suppl.225","article-title":"Sorafenib plus cisplatin and gemcitabine in the treatment of advanced hepatocellular carcinoma (HCC): a phase II study by the Gruppo Oncologico dell'Italia Meridionale (prot. GOIM 2705)","volume":"29","author":"Giuliani","year":"2011","journal-title":"J Clin Oncol"},{"issue":"Suppl 7","key":"10.1016\/j.ejca.2018.04.007_bib15","article-title":"Anti-VEGF drugs combined with gemcitabine-based chemotherapy in treatment of metastatic collecting duct carcinoma","volume":"29","author":"Guo","year":"2011","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2018.04.007_bib16","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1200\/JCO.2004.06.132","article-title":"Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma","volume":"22","author":"Motzer","year":"2004","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2018.04.007_bib17","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s00280-011-1685-x","article-title":"Phase IB study of sorafenib in combination with gemcitabine and cisplatin in patients with refractory solid tumors","volume":"69","author":"Schultheis","year":"2012","journal-title":"Canc Chemother Pharmacol"},{"issue":"25","key":"10.1016\/j.ejca.2018.04.007_bib18","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1200\/JCO.2011.39.7646","article-title":"Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine\/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer","volume":"30","author":"Paz-Ares","year":"2012","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2018.04.007_bib19","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1038\/bjc.2013.432","article-title":"A phase II study of gemcitabine and cisplatin plus sorafenib in patients with advanced biliary adenocarcinomas","volume":"109","author":"Lee","year":"2013","journal-title":"Br J Canc"},{"issue":"3","key":"10.1016\/j.ejca.2018.04.007_bib20","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/bju.12437","article-title":"Prospective randomized double-blind multicentre phase II study comparing gemcitabine and cisplatin plus sorafenib chemotherapy with gemcitabine and cisplatin plus placebo in locally advanced and\/or metastasized urothelial cancer: SUSE (AUO-AB 31\/05)","volume":"113","author":"Krege","year":"2014","journal-title":"BJU Int"},{"issue":"1","key":"10.1016\/j.ejca.2018.04.007_bib21","first-page":"54","article-title":"Collecting duct carcinoma of kidney","volume":"15","author":"Srigley","year":"1998","journal-title":"Semin Diagn Pathol"},{"issue":"5","key":"10.1016\/j.ejca.2018.04.007_bib22","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1016\/S0002-9440(10)64120-X","article-title":"Expression profiling of renal epithelial neoplasms: a method for tumor classification and discovery of diagnostic molecular markers","volume":"158","author":"Young","year":"2001","journal-title":"Am J Pathol"},{"issue":"1","key":"10.1016\/j.ejca.2018.04.007_bib23","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.urology.2004.08.012","article-title":"Renal collecting (Bellini) duct carcinoma displays similar characteristics to upper tract urothelial cell carcinoma","volume":"65","author":"Orsola","year":"2005","journal-title":"Urology"},{"issue":"2","key":"10.1016\/j.ejca.2018.04.007_bib24","doi-asserted-by":"crossref","first-page":"e203","DOI":"10.1016\/j.clgc.2015.11.008","article-title":"Targeted therapy in collecting duct carcinoma of the kidney: a case report and literature review","volume":"14","author":"Yin","year":"2016","journal-title":"Clin Genitourin Canc"},{"issue":"12","key":"10.1016\/j.ejca.2018.04.007_bib25","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1200\/JCO.2010.31.6067","article-title":"Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75","volume":"29","author":"Hahn","year":"2011","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2018.04.007_bib26","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.clgc.2012.10.001","article-title":"Gemcitabine, Cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer","volume":"11","author":"Galsky","year":"2013","journal-title":"Clin Genitourin Canc"},{"issue":"Suppl 6","key":"10.1016\/j.ejca.2018.04.007_bib27","article-title":"Comparison of PFS and safety for Asian compared to North American and European populations in the phase III trial of pazopanib versus sunitinib in patients with treatment-naive RCC (COMPARZ)","volume":"31","author":"Jun","year":"2013","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2018.04.007_bib28","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s11255-013-0468-1","article-title":"Active targeted therapy for metastatic collecting duct carcinoma of the kidney: a case report and review of the literature","volume":"45","author":"Zhao","year":"2013","journal-title":"Int Urol Nephrol"},{"issue":"3","key":"10.1016\/j.ejca.2018.04.007_bib29","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1007\/s10157-012-0589-3","article-title":"Is there a role for targeted therapies in the collecting ducts of Bellini carcinoma? Efficacy data from a retrospective analysis of 7 cases","volume":"16","author":"Procopio","year":"2012","journal-title":"Clin Exp Nephrol"},{"issue":"12","key":"10.1016\/j.ejca.2018.04.007_bib30","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1093\/annonc\/mdt423","article-title":"Triple combination of bevacizumab, gemcitabine and platinum salt in metastatic collecting duct carcinoma","volume":"24","author":"P\u00e9cuchet","year":"2013","journal-title":"Ann Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804918308086?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804918308086?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,29]],"date-time":"2018-08-29T12:36:20Z","timestamp":1535546180000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804918308086"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":30,"alternative-id":["S0959804918308086"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2018.04.007","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sorafenib in combination with gemcitabine plus cisplatin chemotherapy in metastatic renal collecting duct carcinoma: A prospective, multicentre, single-arm, phase 2 study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2018.04.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}